Fagron Posts 10% Revenue Growth in Q1 2026, Driven by M&A and Latin America
Event summary
- Fagron reported Q1 2026 revenue of €263.4 million, up 10.3% year-over-year (15.0% at constant exchange rates).
- Organic growth at constant exchange rates was 3.2%, with Latin America leading at 10.4% growth.
- Completed the Pharmavit acquisition in the Netherlands, with integration progressing as planned.
- FY 2026 guidance maintained: mid- to high-single digit organic sales growth and a REBITDA margin of ~20%.
- North America–Pacific growth slowed to 0.6% due to normalization of GLP-1 related revenues.
The big picture
Fagron’s Q1 2026 results highlight the resilience of its diversified business model, with strong contributions from M&A and Latin America offsetting slower growth in North America. The company’s focus on its Brands strategy and operational excellence initiatives aligns with broader industry trends toward specialization and efficiency in pharmaceutical compounding. The mid- to high-single digit organic growth guidance suggests confidence in sustaining momentum despite regional challenges.
What we're watching
- Regional Dynamics
- Whether Latin America can sustain its strong growth trajectory amid broader market volatility.
- Integration Risk
- The pace at which Pharmavit and other recent acquisitions are integrated into Fagron’s operations.
- Market Normalization
- How the normalization of GLP-1 related revenues will impact North America–Pacific growth in subsequent quarters.
Related topics